Druggability of Proteins in Oncology Targeting Immune Cell Signaling
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".
Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 2798
Special Issue Editor
Interests: tumor immunology; immunotherapy; molecular mechanisms of T lymphocyte signaling; innovative immunological therapeutic concepts; CRISPR/Cas9-mediated gene editing
Special Issue Information
Dear Colleagues,
This Special Issue on “Druggability of Proteins in Oncology Targeting Immune Cell Signaling” will mainly focus on known and novel druggable proteins and their potential to induce a potent antitumor immunity for cancer immunotherapy.
Proteins important for an effective antitumor immune response have been extensively studied in the past two decades and have been shown to induce great response rates in some cancer patients. Still, new pathways/proteins, combinatorial approaches, and methods to target druggable proteins are envisioned as a way forward to extend the benefits of clinical immuno-oncology therapies to a larger number of cancer patients.
We cordially invite authors in the field to submit original research or review articles pertaining to this important and fast-progressing field of biomedicine.
Dr. Victoria Klepsch
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tumor immunology
- druggability of proteins
- immune cell signaling
- antitumor immunity
- immunotherapy
- combinatorial therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
